319 related articles for article (PubMed ID: 22297207)
21. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab in non-small-cell lung cancer: a review.
Planchard D
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1163-79. PubMed ID: 21916570
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer.
Huang Y; Carbone DP
Biochim Biophys Acta; 2015 Apr; 1855(2):193-201. PubMed ID: 25598052
[TBL] [Abstract][Full Text] [Related]
24. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
25. Antiangiogenic therapy in nonsmall cell lung cancer.
Gutierrez M; Giaccone G
Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
[TBL] [Abstract][Full Text] [Related]
26. The potential of antiangiogenic therapy in non-small cell lung cancer.
Giaccone G
Clin Cancer Res; 2007 Apr; 13(7):1961-70. PubMed ID: 17404076
[TBL] [Abstract][Full Text] [Related]
27. Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer.
Gadgeel SM
Clin Lung Cancer; 2012 Mar; 13(2):96-106. PubMed ID: 22056889
[TBL] [Abstract][Full Text] [Related]
28. [Anti-angiogenic agents of lung cancer].
Wakuda K; Takahashi T
Gan To Kagaku Ryoho; 2014 Feb; 41(2):162-71. PubMed ID: 24743195
[TBL] [Abstract][Full Text] [Related]
29. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
Newton HB
Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
[TBL] [Abstract][Full Text] [Related]
30. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.
Eskens FA; Verweij J
Eur J Cancer; 2006 Dec; 42(18):3127-39. PubMed ID: 17098419
[TBL] [Abstract][Full Text] [Related]
31. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.
Gridelli C; Maione P; Rossi A; De Marinis F
Oncologist; 2007 Oct; 12(10):1183-93. PubMed ID: 17962612
[TBL] [Abstract][Full Text] [Related]
32. Targeting VEGF in lung cancer.
Das M; Wakelee H
Expert Opin Ther Targets; 2012 Apr; 16(4):395-406. PubMed ID: 22439677
[TBL] [Abstract][Full Text] [Related]
33. Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches.
Gille J
Exp Dermatol; 2006 Mar; 15(3):175-86. PubMed ID: 16480425
[TBL] [Abstract][Full Text] [Related]
34. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
35. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
Maione P; Gridelli C; Troiani T; Ciardiello F
Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster.
Mountzios G; Pentheroudakis G; Carmeliet P
Pharmacol Ther; 2014 Feb; 141(2):117-24. PubMed ID: 24076268
[TBL] [Abstract][Full Text] [Related]
37. Combining antiangiogenics to overcome resistance: rationale and clinical experience.
Moreno Garcia V; Basu B; Molife LR; Kaye SB
Clin Cancer Res; 2012 Jul; 18(14):3750-61. PubMed ID: 22547772
[TBL] [Abstract][Full Text] [Related]
38. Emerging antiangiogenic agents in lung cancer.
Lee D; Heymach JV
Clin Lung Cancer; 2006 Mar; 7(5):304-8. PubMed ID: 16640800
[TBL] [Abstract][Full Text] [Related]
39. Targeted therapies in bladder cancer--an update.
Black PC; Agarwal PK; Dinney CP
Urol Oncol; 2007; 25(5):433-8. PubMed ID: 17826665
[TBL] [Abstract][Full Text] [Related]
40. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Sosman JA; Puzanov I; Atkins MB
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]